Johny Bajgai1, Jing Xingyu1,2, Ailyn Fadriquela1,3, Rahima Begum1, Dong Heui Kim1, Cheol-Su Kim1, Soo-Ki Kim4, Kyu-Jae Lee5,6. 1. Department of Environmental Medical Biology, Wonju College of Medicine, Yonsei University, Wonju, Gangwon-do, 26426, Republic of Korea. 2. Department of Global Medical Science, Graduate School, Yonsei University, Wonju, Gangwon-do, 26426, Republic of Korea. 3. Department of Laboratory Medicine, Wonju College of Medicine, Yonsei University, Wonju, Gangwon-do, 26426, Republic of Korea. 4. Department of Microbiology, Wonju College of Medicine, Yonsei University, Wonju, Gangwon-do, 26426, Republic of Korea. 5. Department of Environmental Medical Biology, Wonju College of Medicine, Yonsei University, Wonju, Gangwon-do, 26426, Republic of Korea. medbio9@gmail.com. 6. Institute for Poverty Alleviation and International Development, Yonsei University, Wonju Campus, Wonju, Gangwon-do, 26493, Republic of Korea. medbio9@gmail.com.
Abstract
BACKGROUND: Atopic dermatitis (AD) is a chronic allergic inflammatory skin disease characterized by complex pathogenesis including skin barrier dysfunction, immune-redox disturbances, and pruritus. Prolonged topical treatment with medications such as corticosteroids, calcineurin inhibitors, and T-cell inhibitors may have some potential side-effects. To this end, many researchers have explored numerous alternative therapies using natural products and mineral compounds with antioxidant or immunomodulatory effects to minimize toxicity and adverse-effects. In the current study, we investigated the effects of mineral complex material (MCM) treatment on 2, 4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in SKH-1 hairless mice. METHODS: Animals were divided into four groups; normal control (NC), negative control treated with DNCB only (DNCB only), positive control treated with DNCB and tacrolimus ointment (PC) and experimental group treated with DNCB and MCM patch (MCM). Skin inflammation and lesion severity were investigated through analyses of skin parameters (barrier score and strength, moisture and trans-epidermal water loss level), histopathology, immunoglobulin E, and cytokines. In addition, reactive oxygen species (ROS), nitric oxide (NO), glutathione peroxidase (GPx), and catalase (CAT) levels were measured in both serum and skin lysate. RESULTS: Our results demonstrates that MCM patch improved the progression of AD-like skin lesions by significantly increasing skin barrier strength and decreasing trans-epidermal water loss. Additionally, dermal administration of MCM patch significantly reduced epidermal thickness, ROS, and NO levels in skin lysate. Furthermore, we found that MCM suppressed the levels of AD-involved (Th1 and Th2) cytokines such as IL-2, IFN-γ, and IL-4 in blood. In addition, the levels of other Th1, and Th2 and inflammatory cytokines such as IL-1β, TNF-α, IL-6, IL-12(p70) and IL-10 were found lowest in the MCM group than in the DNCB only and PC groups. Moreover, we found total serum IgE level significantly increased after DNCB treatment, but decreased in the PC and MCM groups. CONCLUSION: Taken together, our findings suggest that MCM application may have beneficial effects either systemic or regional on DNCB-induced AD lesional skin via regulation of the skin barrier function and immune-redox response.
BACKGROUND:Atopic dermatitis (AD) is a chronic allergic inflammatory skin disease characterized by complex pathogenesis including skin barrier dysfunction, immune-redox disturbances, and pruritus. Prolonged topical treatment with medications such as corticosteroids, calcineurin inhibitors, and T-cell inhibitors may have some potential side-effects. To this end, many researchers have explored numerous alternative therapies using natural products and mineral compounds with antioxidant or immunomodulatory effects to minimize toxicity and adverse-effects. In the current study, we investigated the effects of mineral complex material (MCM) treatment on 2, 4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in SKH-1 hairless mice. METHODS: Animals were divided into four groups; normal control (NC), negative control treated with DNCB only (DNCB only), positive control treated with DNCB and tacrolimus ointment (PC) and experimental group treated with DNCB and MCM patch (MCM). Skin inflammation and lesion severity were investigated through analyses of skin parameters (barrier score and strength, moisture and trans-epidermal water loss level), histopathology, immunoglobulin E, and cytokines. In addition, reactive oxygen species (ROS), nitric oxide (NO), glutathione peroxidase (GPx), and catalase (CAT) levels were measured in both serum and skin lysate. RESULTS: Our results demonstrates that MCM patch improved the progression of AD-like skin lesions by significantly increasing skin barrier strength and decreasing trans-epidermal water loss. Additionally, dermal administration of MCM patch significantly reduced epidermal thickness, ROS, and NO levels in skin lysate. Furthermore, we found that MCM suppressed the levels of AD-involved (Th1 and Th2) cytokines such as IL-2, IFN-γ, and IL-4 in blood. In addition, the levels of other Th1, and Th2 and inflammatory cytokines such as IL-1β, TNF-α, IL-6, IL-12(p70) and IL-10 were found lowest in the MCM group than in the DNCB only and PC groups. Moreover, we found total serum IgE level significantly increased after DNCB treatment, but decreased in the PC and MCM groups. CONCLUSION: Taken together, our findings suggest that MCM application may have beneficial effects either systemic or regional on DNCB-induced AD lesional skin via regulation of the skin barrier function and immune-redox response.
Entities:
Keywords:
Atopic dermatitis; Dinitrochlorobenzene; Immune redox; Inflammatory disease; Mineral complex material patch
Authors: Michael J Cork; Simon G Danby; Yiannis Vasilopoulos; Jonathan Hadgraft; Majella E Lane; Manar Moustafa; Richard H Guy; Alice L Macgowan; Rachid Tazi-Ahnini; Simon J Ward Journal: J Invest Dermatol Date: 2009-06-04 Impact factor: 8.551
Authors: Donald Y M Leung; Mark Boguniewicz; Michael D Howell; Ichiro Nomura; Qutayba A Hamid Journal: J Clin Invest Date: 2004-03 Impact factor: 14.808
Authors: Wenbing Zhi; Chun Li; Hong Zhang; Yiding Zhao; Shiyu Zong; Qiqi Liu; Jie Zhou; Chunliu Wang; Tingting Sun; Yang Liu; Ye Li Journal: Evid Based Complement Alternat Med Date: 2022-05-18 Impact factor: 2.650